Dissociable effect of acute varenicline on tonic versus cue-provoked craving in non-treatment-motivated heavy smokers

Drug and Alcohol Dependence

Volumn 130, Issue 1-3, 2013, Pages 135-141

  Hitsman, Brian ^a   Hogarth, Lee ^b   Tseng, Li Jung ^c   Teige, Jordan C ^a   Shadel, William G ^d   DiBenedetti, Dana Britt ^e   Danto, Spencer ^c   Lee, Theodore C ^c   Price, Lawrence H ^f   Niaura, Raymond ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PFIZER INC   (United States)

^d RAND CORPORATION   (United States)

^e RTI HEALTH SOLUTIONS   (United States)

^f BROWN UNIVERSITY   (United States)

^g American Legacy Foundation   (United States)

Author keywords

Affect; Craving; Cue reactivity; Nicotine withdrawal; Smoking cessation; Varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; AFFECT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BRADYCARDIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HEADACHE; HUMAN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; SMOKING CESSATION; SOMNOLENCE; TACHYCARDIA; VOMITING; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; BEHAVIOR, ADDICTIVE; BENZAZEPINES; CROSS-OVER STUDIES; CUES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; QUINOXALINES; SMOKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877067849     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.10.021     Document Type: Article

References (52)

1. Balleine B.W., Leung B.K., Ostlund S.B. The orbitofrontal cortex, predicted value, and choice. Ann. N. Y. Acad. Sci. 2011, 1239:43-50.
2. Brandon T.H., Drobes D.J., Unrod M., Heckman B.W., Oliver J.A., Roetzheim R.C., Karver S.B., Small B.J. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology (Berl.) 2011, 218:391-403.
3. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2011, CD006103.
4. Chandra S., Scharf D., Shiffman S. Within-day temporal patterns of smoking, withdrawal symptoms, and craving. Drug Alcohol Depend. 2011, 117:118-125.
5. Colwill R.M., Rescorla R.A. Effect of reinforcer devaluation on discriminative control of instrumental behavior. J. Exp. Psychol. Anim. Behav. Processes 1990, 16:40-47.
6. Corbit L.H., Janak P.H., Balleine B.W. General and outcome-specific forms of Pavlovian-instrumental transfer: the effect of shifts in motivational state and inactivation of the ventral tegmental area. Eur. J. Neurosci. 2007, 26:3141-3149.
7. Delamater A.R. Outcome-selective effects of intertrial reinforcement in Pavlovian appetitive conditioning with rats. Anim. Learn. Behav. 1995, 23:31-39.
8. Drobes D.J., Tiffany S.T. Induction of smoking urge through imaginal and in vivo procedures: physiological and self-report manifestations. J. Abnorm. Psychol. 1997, 106:15-25.
9. Faessel H.M., Smith B.J., Gibbs M.A., Gobey J.S., Clark D.J., Burstein A.H. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J. Clin. Pharmacol. 2006, 46:991-998.
10. Fagerström K.O., Heatherton T.F., Kozlowski L.T. Nicotine addiction and its assessment. Ear Nose Throat J. 1990, 69:763-765.
11. Ferguson S.G., Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J. Subst. Abuse Treat. 2009, 36:235-243.
12. Franklin T., Wang Z., Suh J.J., Hazan R., Cruz J., Li Y., Goldman M., Detre J.A., O'Brien C.P., Childress A.R. Effects of varenicline on smoking cue-triggered neural and craving responses. Arch. Gen. Psychiatry 2011, 68:516-526.
13. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., Reeves K.R. Varenicline, an alpha4 beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
14. Hajek P., McRobbie H.J., Myers K.E., Stapleton J., Dhanji A.R. Use of varenicline for 4weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch. Intern. Med. 2011, 171:770-777.
15. Havermans R.C., Debaere S., Smulders F.T., Wiers R.W., Jansen A.T. Effect of cue exposure, urge to smoke, and nicotine deprivation on cognitive performance in smokers. Psychol. Addict. Behav. 2003, 17:336-339.
16. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
17. Hellemans K.G.C., Dickinson A., Everitt B.J. Motivational control of heroin seeking by conditioned stimuli associated with withdrawal and heroin taking by rats. Behav. Neurosci. 2006, 120:103-114.
18. Hogarth L. Goal-directed and transfer-cue-elicited drug-seeking are dissociated by pharmacotherapy: evidence for independent additive controllers. J. Exp. Psychol. Anim. Behav. Processes 2012, 38:266-278.
19. Hogarth L., Chase H.W. Parallel goal-directed and habitual control of human drug-seeking: implications for dependence vulnerability. J. Exp. Psychol. Anim. Behav. Processes 2011, 37:261-276.
20. Hogarth L., Dickinson A., Duka T. The associative basis of cue-elicited drug taking in humans. Psychopharmacology (Berl.) 2010, 208:337-351.
21. Holland P.C. Relations between Pavlovian-instrumental transfer and reinforcer devaluation. J. Exp. Psychol. Anim. Behav. Processes 2004, 30:104-117.
22. Hughes J.R., Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry 1986, 43:289-294.
23. Hussain S., Zawertailo L., Busto U., Zack M., Farvolden P., Selby P. The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: a randomized controlled trial in unmotivated smokers. Addict. Behav. 2010, 35:164-167.
24. Hutcheson D.M., Everitt B.J., Robbins T.W., Dickinson A. The role of withdrawal in heroin addiction: enhances reward or promotes avoidance?. Nat. Neurosci. 2001, 4:943-947.
25. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., Billing C.B., Gong J., Reeves K.R. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
26. Maude-Griffin P., Tiffany S.T. Production of smoking urges through imagery: the impact of affect and smoking abstinence. Exp. Clin. Psychopharmacol. 1996, 4:198-208.
27. Morissette S.B., Palfai T.P., Gulliver S.B., Spiegel D.A., Barlow D.H. Effects of transdermal nicotine during imaginal exposure to anxiety and smoking cues in college smokers. Psychol. Addict. Behav. 2005, 19:192-198.
28. Mucha R.F., Pauli P., Angrilli A. Conditioned responses elicited by experimentally produced cues for smoking. Can. J. Physiol. Pharmacol. 1998, 76:259-268.
29. Munafò M.R., Hitsman B. What's the matter with cue-induced craving?. A commentary on Perkins. Addiction 2010, 105:1860-1861.
30. Niaura R., Shadel W.G., Abrams D.B., Monti P.M., Rohsenow D.J., Sirota A. Individual differences in cue reactivity among smokers trying to quit: effects of gender and cue type. Addict. Behav. 1998, 23:209-224.
31. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J., Anziano R., Reeves K.R. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch. Intern. Med. 2006, 166:1561-1568.
32. Patterson F., Jepson C., Strasser A.A., Loughead J., Perkins K.A., Gur R.C., Frey J.M., Siegel S., Lerman C. Varenicline improves mood and cognition during smoking abstinence. Biol. Psychiatry 2009, 65:144-149.
33. Perkins K.A. Does smoking cue-induced craving tell us anything important about nicotine dependence?. Addiction 2009, 104:1610-1616.
34. Perkins K.A., Mercincavage M., Fonte C.A., Lerman C. Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychoph. (Berl.) 2010, 210:45-51.
35. Pomerleau C.S., Teuscher F., Goeters S., Pomerleau O.F. Effects of nicotine abstinence and menstrual phase on task performance. Addict. Behav. 1994, 19:357-362.
36. Rescorla R. Transfer of instrumental control mediated by a devalued outcome. Anim. Learn. Behav. 1994, 22:27-33.
37. Rohsenow D.J., Monti P.M., Hutchison K.E., Swift R.M., MacKinnon S.V., Sirota A.D., Kaplan G.B. High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Exp. Clin. Psychopharmacol. 2007, 15:81-92.
38. Rollema H., Chambers L.K., Coe J.W., Glowa J., Hurst R.S., Lebel L.A., Lu Y., Mansbach R.S., Mather R.J., Rovetti C.C., Sands S.B., Schaeffer E., Schulz D.W., Tingley F.D., Williams K.E. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52:985-994.
39. Sayette M.A., Hufford M.R. Effects of cue exposure and deprivation on cognitive resources in smokers. J. Abnorm. Psychol. 1994, 103:812-818.
40. Shadel W.G., Martino S.C., Setodji C., Cervone D., Witkiewitz K., Beckjord E.B., Scharf D., Shih R. Lapse-induced surges in craving influence relapse in adult smokers: an experimental investigation. Health Psychol. 2011, 30:588-596.
41. Shiffman S. Comments on craving. Addiction 2000, 95(Suppl. 2):S171-S175.
42. Shiffman S., Engberg J.B., Paty J.A., Perz W.G., Gnys M., Kassel J.D., Hickcox M. A day at a time: predicting smoking lapse from daily urge. J. Abnorm. Psychol. 1997, 106:104-116.
43. Shiffman S., Paty J.A., Gnys M., Kassel J.A., Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. J. Consult. Clin. Psychol. 1996, 64:366-379.
44. Shiffman S., Shadel W.G., Niaura R., Khayrallah M.A., Jorenby D.E., Ryan C.F., Ferguson C.L. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl.) 2003, 166:343-350.
45. Sofuoglu M., Herman A.I., Mooney M., Waters A.J. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl.) 2009, 207:153-162.
46. Thornley S., McRobbie H., Lin R.B., Bullen C., Hajek P., Laugesen M., Senior H., Whittaker R. A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction. Nicotine Tob. Res. 2009, 11:715-721.
47. Tiffany S.T., Cox L.S., Elash C.A. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J. Consult. Clin. Psychol. 2000, 68:233-240.
48. Tonstad S., Tønnesen P., Hajek P., Williams K.E., Billing C.B., Reeves K.R. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296:64-71.
49. Waters A.J., Shiffman S., Sayette M.A., Paty J.A., Gwaltney C.J., Balabanis M.H. Cue-provoked craving and nicotine replacement therapy in smoking cessation. J. Consult. Clin. Psychol. 2004, 72:1136-1143.
50. Watson D., Clark L.A., Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J. Pers. Soc. Psychol. 1988, 54:1063-1070.
51. West R., Baker C.L., Cappelleri J.C., Bushmakin A.G. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychoph. (Berl.) 2008, 197:371-377.
52. Witkiewitz K., Marlatt G.A. Relapse prevention for alcohol and drug problems: that was Zen, this is Tao. Am. Psychol. 2004, 59:224-235.